Below is a list of clinical trials currently underway in Hairy Cell Leukemia. Each link will take you to ClinicalTrials.gov which is a registry of federally and privately supported clinical trials in the United States and around the world. ClinicalTrials.gov is a service of the U.S. National Institutes of Health. We recommend that you contact your physician and/or one of our Centers of Excellence to see if a clinical trial is right for you.

BL22 Immunotoxin in Treating Patients With Hairy Cell Leukemia That Has Relapsed or Not Responded to Treatment

Condition: Leukemia
Intervention: Biological: BL22 immunotoxin

BL22 Immunotoxin in Treating Patients With HCL

2CDA With Rituximab in Hairy Cell Leukemia

Condition: Leukemia
Interventions: Drug: Cladribine (2-CDA); Drug: Rituximab

2CDA With Rituximab in HCL

A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia

Condition: Hairy Cell Leukemia
Intervention: Biological: CAT 8015

A Phase I, Multicenter Dose Escalation

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Condition: Leukemia
Interventions: Biological: rituximab; Drug: cladribine

Cladribine and Rituximab in Treating Patients With HCL

LMB-2 Immunotoxin in Treating Patients With Recurrent or Refractory Hairy Cell Leukemia

Condition: Leukemia
Interventions: Biological: LMB-2 immunotoxin; Other: pharmacological study

LMB-2 Immunotoxin in Treating Patients With Recurrent or Refractory HCL

Safety Study of CAT-8015 Immunotoxin in Patients With HCL With Advance Disease

Conditions: Leukemia; Hairy Cell Leukemia; HCL
Interventions: Drug: Immunotoxin therapy; Drug: CAT-8015 Immunotoxin; Procedure: Biological therapy

CAT-8015 Immunotoxin in Patients With HCL